In an animal model with systemic inflammation, the administration of a STAT3 inhibitor not only protects against microglial activation and neuroinflammation, characteristic of AD pathophysiology, but also reduces beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) protein levels [45]. This evidence concerns the gene STAT3 and Alzheimer disease.